Type I Interferon in the Pathogenesis of Lupus

Investigations of patients with systemic lupus erythematosus have applied insights from studies of the innate immune response to define IFN-I, with IFN-α as the dominant mediator, as central to the pathogenesis of this prototype systemic autoimmune disease. Genetic association data identify regulators of nucleic acid degradation and components of TLR-independent, endosomal TLR-dependent, and IFN-I–signaling pathways as contributors to lupus disease susceptibility. Together with a gene expression signature characterized by IFN-I–induced gene transcripts in lupus blood and tissue, those data support the conclusion that many of the immunologic and pathologic features of this disease are a consequence of a persistent self-directed immune reaction driven by IFN-I and mimicking a sustained antivirus response. This expanding knowledge of the role of IFN-I and the innate immune response suggests candidate therapeutic targets that are being tested in lupus patients.

[1]  J. Liesveld,et al.  Neutrophil-Mediated IFN Activation in the Bone Marrow Alters B Cell Development in Human and Murine Systemic Lupus Erythematosus , 2014, The Journal of Immunology.

[2]  G. Barber STING-dependent cytosolic DNA sensing pathways. , 2014, Trends in immunology.

[3]  C. Günther,et al.  Aicardi–Goutières syndrome: a model disease for systemic autoimmunity , 2014, Clinical and experimental immunology.

[4]  A. Vanderver,et al.  Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study , 2013, The Lancet Neurology.

[5]  D. Kono,et al.  TLRs and interferons: a central paradigm in autoimmunity. , 2013, Current opinion in immunology.

[6]  W. Stohl Future prospects in biologic therapy for systemic lupus erythematosus , 2013, Nature Reviews Rheumatology.

[7]  Leonie Unterholzner The interferon response to intracellular DNA: why so many receptors? , 2013, Immunobiology.

[8]  M. Kaplan Role of neutrophils in systemic autoimmune diseases , 2013, Arthritis Research & Therapy.

[9]  R. Fischer-Betz,et al.  Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) – results from a nationwide cohort in Germany (GRAID) , 2013, Lupus.

[10]  G. Barber,et al.  DDX24 Negatively Regulates Cytosolic RNA-Mediated Innate Immune Signaling , 2013, PLoS pathogens.

[11]  G. Hartmann,et al.  Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing. , 2013, Immunity.

[12]  B. Barnes,et al.  Bioinformatics Analysis of the Factors Controlling Type I IFN Gene Expression in Autoimmune Disease and Virus-Induced Immunity , 2013, Front. Immunol..

[13]  Sean L. Evans,et al.  Modulation of LINE-1 and Alu/SVA Retrotransposition by Aicardi-Goutières Syndrome-Related SAMHD1 , 2013, Cell reports.

[14]  H. Rammensee,et al.  TLR9 independent interferon α production by neutrophils on NETosis in response to circulating chromatin, a key lupus autoantigen , 2013, Annals of the rheumatic diseases.

[15]  K. Kirou,et al.  Anti-interferon alpha treatment in SLE. , 2013, Clinical immunology.

[16]  Werner Müller,et al.  Mouse SAMHD1 Has Antiretroviral Activity and Suppresses a Spontaneous Cell-Intrinsic Antiviral Response , 2013, Cell reports.

[17]  H. Anders,et al.  The antiviral cytokines IFN-α and IFN-β modulate parietal epithelial cells and promote podocyte loss: implications for IFN toxicity, viral glomerulonephritis, and glomerular regeneration. , 2013, The American journal of pathology.

[18]  D. Absher,et al.  Genome-Wide DNA Methylation Analysis of Systemic Lupus Erythematosus Reveals Persistent Hypomethylation of Interferon Genes and Compositional Changes to CD4+ T-cell Populations , 2013, PLoS genetics.

[19]  B. Schmidt,et al.  Identification of novel oligonucleotides from mitochondrial DNA that spontaneously induce plasmacytoid dendritic cell activation , 2013, Journal of leukocyte biology.

[20]  L. Davis,et al.  SLE Peripheral Blood B Cell, T Cell and Myeloid Cell Transcriptomes Display Unique Profiles and Each Subset Contributes to the Interferon Signature , 2013, PloS one.

[21]  W. White,et al.  Pharmacogenomics and Translational Simulations to Bridge Indications for an Anti‐Interferon‐α Receptor Antibody , 2013, Clinical pharmacology and therapeutics.

[22]  J. Wren,et al.  Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naïve CD4+ T cells from lupus patients. , 2013, Journal of autoimmunity.

[23]  V. Pascual,et al.  Current perspectives on systems immunology approaches to rheumatic diseases. , 2013, Arthritis and rheumatism.

[24]  V. Hornung,et al.  cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING , 2013, Nature.

[25]  B. Beutler,et al.  Role of Nucleic Acid–Sensing TLRs in Diverse Autoantibody Specificities and Anti-Nuclear Antibody–Producing B Cells , 2013, The Journal of Immunology.

[26]  R. Moon,et al.  A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. , 2013, The Journal of clinical investigation.

[27]  M. Wong,et al.  Systemic lupus erythematosus due to C1q deficiency with progressive encephalopathy, intracranial calcification and acquired moyamoya cerebral vasculopathy , 2013, Lupus.

[28]  R. Schreiber,et al.  Persistent LCMV Infection Is Controlled by Blockade of Type I Interferon Signaling , 2013, Science.

[29]  B. Aronow,et al.  Blockade of Chronic Type I Interferon Signaling to Control Persistent LCMV Infection , 2013, Science.

[30]  C. Alpers,et al.  Increased Ribonuclease Expression Reduces Inflammation and Prolongs Survival in TLR7 Transgenic Mice , 2013, The Journal of Immunology.

[31]  M. Lederman,et al.  Interferon-α Is the Primary Plasma Type-I IFN in HIV-1 Infection and Correlates with Immune Activation and Disease Markers , 2013, PloS one.

[32]  Zhijian J. Chen,et al.  Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway , 2013, Science.

[33]  Dong Yu,et al.  Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9 , 2013, Nucleic acids research.

[34]  Eric Hachulla,et al.  Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid. , 2013, Arthritis and rheumatism.

[35]  C. Carmona-Rivera,et al.  Neutrophil Extracellular Trap–Associated Protein Activation of the NLRP3 Inflammasome Is Enhanced in Lupus Macrophages , 2013, The Journal of Immunology.

[36]  M. Longobardi,et al.  Inhibition of the de-myelinating properties of Aicardi-Goutières syndrome lymphocytes by cathepsin D silencing. , 2013, Biochemical and biophysical research communications.

[37]  Larissa B. Thackray,et al.  IRF-3, IRF-5, and IRF-7 Coordinately Regulate the Type I IFN Response in Myeloid Dendritic Cells Downstream of MAVS Signaling , 2013, PLoS pathogens.

[38]  R. Schreiber,et al.  Anti–IFN-α/β Receptor Antibody Treatment Ameliorates Disease in Lupus-Predisposed Mice , 2012, The Journal of Immunology.

[39]  D. Green,et al.  Noncanonical autophagy is required for type I interferon secretion in response to DNA-immune complexes. , 2012, Immunity.

[40]  Nan Yan,et al.  Trex1 regulates lysosomal biogenesis and interferon-independent activation of antiviral genes , 2012, Nature Immunology.

[41]  M. Gilliet,et al.  Cytosolic sensing of extracellular self-DNA transported into monocytes by the antimicrobial peptide LL37. , 2012, Blood.

[42]  R. Maciuca,et al.  Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. , 2012, Arthritis and rheumatism.

[43]  B. Diamond,et al.  Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. , 2012, Arthritis and rheumatism.

[44]  M. Shlomchik,et al.  NADPH Oxidase Inhibits the Pathogenesis of Systemic Lupus Erythematosus , 2012, Science Translational Medicine.

[45]  C. Cheadle,et al.  Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases , 2012, Proceedings of the National Academy of Sciences.

[46]  J. Buyon,et al.  Brief Report: IRF5 systemic lupus erythematosus risk haplotype is associated with asymptomatic serologic autoimmunity and progression to clinical autoimmunity in mothers of children with neonatal lupus. , 2012, Arthritis and rheumatism.

[47]  S. Bolland,et al.  Dual signaling by innate and adaptive immune receptors is required for TLR7-induced B-cell–mediated autoimmunity , 2012, Proceedings of the National Academy of Sciences.

[48]  L. Criswell,et al.  Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus , 2012, Arthritis Research & Therapy.

[49]  B. Sundaram,et al.  Type I Interferons Are Associated with Subclinical Markers of Cardiovascular Disease in a Cohort of Systemic Lupus Erythematosus Patients , 2012, PloS one.

[50]  D. Stetson,et al.  Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. , 2012, Immunity.

[51]  M. David,et al.  Immunomodulatory functions of type I interferons , 2012, Nature Reviews Immunology.

[52]  M. Petri,et al.  A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. , 2011, Arthritis and rheumatism.

[53]  A. Syvänen,et al.  Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with Systemic Lupus Erythematosus , 2011, PLoS genetics.

[54]  S. Kong,et al.  Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis , 2011, Genes and Immunity.

[55]  Alexander R. Abbas,et al.  Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. , 2011, Arthritis and rheumatism.

[56]  M. Jolly,et al.  Autoimmune Disease Risk Variant of IFIH1 Is Associated with Increased Sensitivity to IFN-α and Serologic Autoimmunity in Lupus Patients , 2011, The Journal of Immunology.

[57]  S. Greenberg,et al.  Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway , 2011, Annals of the rheumatic diseases.

[58]  M. Petri,et al.  Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study , 2011, Annals of the rheumatic diseases.

[59]  E. Lourenço,et al.  Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity , 2011, Arthritis research & therapy.

[60]  C D Langefeld,et al.  Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort , 2011, Genes and Immunity.

[61]  Hong Zhang,et al.  Genetic association of PRDM1-ATG5 intergenic region and autophagy with systemic lupus erythematosus in a Chinese population , 2011, Annals of the rheumatic diseases.

[62]  T. Veenstra,et al.  Cutting Edge: Ku70 Is a Novel Cytosolic DNA Sensor That Induces Type III Rather Than Type I IFN , 2011, The Journal of Immunology.

[63]  A. Marshak‐Rothstein,et al.  Toll-like receptor driven B cell activation in the induction of systemic autoimmunity. , 2011, Seminars in immunology.

[64]  L. Rönnblom,et al.  The type I interferon system in the development of lupus. , 2011, Seminars in immunology.

[65]  Sarah E. Ewald,et al.  Nucleic acid recognition by the innate immune system. , 2011, Annual review of immunology.

[66]  Tomoki Ito,et al.  Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNA–Peptide Complexes in Systemic Lupus Erythematosus , 2011, Science Translational Medicine.

[67]  J. Connolly,et al.  Netting Neutrophils Are Major Inducers of Type I IFN Production in Pediatric Systemic Lupus Erythematosus , 2011, Science Translational Medicine.

[68]  C. Bao,et al.  Interferon-α priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-α and atherosclerosis in lupus. , 2011, Arthritis and rheumatism.

[69]  M. Si-Tahar,et al.  A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients , 2011, EMBO Molecular Medicine.

[70]  N. Kadowaki,et al.  Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis. , 2011, Blood.

[71]  B. Tsao,et al.  Genetic susceptibility to systemic lupus erythematosus in the genomic era , 2010, Nature Reviews Rheumatology.

[72]  Timothy B. Niewold,et al.  Interferon Alpha in Systemic Lupus Erythematosus , 2010, Journal of biomedicine & biotechnology.

[73]  G. Doria,et al.  APC Activation by IFN-α Decreases Regulatory T Cell and Enhances Th Cell Functions , 2010, The Journal of Immunology.

[74]  B. Huang,et al.  Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice , 2010, Lupus.

[75]  P. Brown,et al.  Dissecting Interferon-Induced Transcriptional Programs in Human Peripheral Blood Cells , 2010, PloS one.

[76]  W. Mccune,et al.  A Distinct Subset of Proinflammatory Neutrophils Isolated from Patients with Systemic Lupus Erythematosus Induces Vascular Damage and Synthesizes Type I IFNs , 2010, The Journal of Immunology.

[77]  W. White,et al.  A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. , 2010, Journal of the American Academy of Dermatology.

[78]  M. Crow Long interspersed nuclear elements (LINE-1): Potential triggers of systemic autoimmune disease , 2010, Autoimmunity.

[79]  Yihong Yao,et al.  Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus , 2009, Human genomics and proteomics : HGP.

[80]  Y. Crow,et al.  Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity. , 2009, Human molecular genetics.

[81]  M. Crow Developments in the clinical understanding of lupus , 2009, Arthritis research & therapy.

[82]  P. Gregersen,et al.  Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. , 2009, Arthritis and rheumatism.

[83]  M. Petri,et al.  Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus , 2009, Lupus.

[84]  P. Kiener,et al.  Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. , 2009, Arthritis and rheumatism.

[85]  Eshrat S. Emamian,et al.  Peripheral blood gene expression profiling in Sjögren’s syndrome , 2009, Genes and Immunity.

[86]  T. Niewold,et al.  Age- and gender-specific modulation of serum osteopontin and interferon-α by osteopontin genotype in systemic lupus erythematosus , 2009, Genes and Immunity.

[87]  Li Li,et al.  The lupus susceptibility gene kallikrein down-modulates antibody-mediated glomerulonephritis , 2009, Genes and Immunity.

[88]  T. Niewold,et al.  Cutting Edge: Autoimmune Disease Risk Variant of STAT4 Confers Increased Sensitivity to IFN-α in Lupus Patients In Vivo1 , 2009, The Journal of Immunology.

[89]  T. Heidmann,et al.  Trex1 Prevents Cell-Intrinsic Initiation of Autoimmunity , 2008, Cell.

[90]  J. Harley,et al.  Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. , 2008, Arthritis and rheumatism.

[91]  Virginia Pascual,et al.  A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. , 2008, Immunity.

[92]  S. Akira,et al.  Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid–inducible gene-I and melanoma differentiation–associated gene 5 , 2008, The Journal of experimental medicine.

[93]  R. Coffman,et al.  Development of TLR inhibitors for the treatment of autoimmune diseases , 2008, Immunological reviews.

[94]  R. Coffman,et al.  PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation , 2008, The Journal of experimental medicine.

[95]  D. Barnes,et al.  Trex1 Exonuclease Degrades ssDNA to Prevent Chronic Checkpoint Activation and Autoimmune Disease , 2007, Cell.

[96]  K. Honda,et al.  DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response , 2007, Nature.

[97]  F. Houssiau,et al.  Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. , 2007, Arthritis and rheumatism.

[98]  L. Audoly,et al.  Toll-like receptor 9–dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE , 2007, Nature Immunology.

[99]  D. Furst,et al.  Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[100]  J. Shupe,et al.  Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. , 2006, Immunity.

[101]  M. Crow,et al.  Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. , 2006, Arthritis and rheumatism.

[102]  L. Rönnblom,et al.  Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA. , 2006, Arthritis and rheumatism.

[103]  S. Akira,et al.  "Endogenous adjuvant" activity of the RNA components of lupus autoantigens Sm/RNP and Ro 60. , 2006, Arthritis and rheumatism.

[104]  R. Medzhitov,et al.  Toll-dependent selection of microbial antigens for presentation by dendritic cells , 2006, Nature.

[105]  X. Mariette,et al.  B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome , 2006, Arthritis research & therapy.

[106]  S. Akira,et al.  Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus , 2005, The Journal of experimental medicine.

[107]  A. Blangy,et al.  Interferon-α and -β differentially regulate osteoclastogenesis: Role of differential induction of chemokine CXCL11 expression , 2005 .

[108]  M. Peterson,et al.  Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. , 2005, Arthritis and rheumatism.

[109]  D. Golenbock,et al.  Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. , 2005, The Journal of clinical investigation.

[110]  M. Peterson,et al.  Coordinate overexpression of interferon‐α–induced genes in systemic lupus erythematosus , 2004 .

[111]  M. Crow,et al.  Interferon-α in systemic lupus erythematosus , 2004 .

[112]  L. Calabrese,et al.  Induction of Clinical Autoimmune Disease by Therapeutic Interferon-α , 2003, Autoimmunity.

[113]  M. Crow,et al.  Microarray Analysis of Interferon-regulated Genes in SLE , 2003, Autoimmunity.

[114]  R Hal Scofield,et al.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus. , 2003, The New England journal of medicine.

[115]  M. Crow,et al.  Microarray analysis of gene expression in lupus , 2003, Arthritis research & therapy.

[116]  Guo-Ping Zhou,et al.  Triggering the Interferon Antiviral Response Through an IKK-Related Pathway , 2003, Science.

[117]  C. Bao,et al.  Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray , 2003, Genes and Immunity.

[118]  Virginia Pascual,et al.  Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.

[119]  G. Karypis,et al.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[120]  Virginia Pascual,et al.  Induction of Dendritic Cell Differentiation by IFN-α in Systemic Lupus Erythematosus , 2001, Science.

[121]  F. Lund-Johansen,et al.  Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. , 2001, The American journal of pathology.

[122]  R. Medzhitov,et al.  The Toll-receptor family and control of innate immunity. , 1999, Current opinion in immunology.

[123]  B. Williams,et al.  Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays , 1998 .

[124]  C. Morimoto,et al.  Cellular mechanism of DNA-specific antibody synthesis by lymphocytes from systemic lupus erythematosus patients. , 1984, Arthritis and rheumatism.

[125]  J. Steitz,et al.  Deciphering the mysteries of RNA-containing lupus antigens. , 1982, Arthritis and rheumatism.

[126]  A. Notkins,et al.  Immune interferon in the circulation of patients with autoimmune disease. , 1979, The New England journal of medicine.

[127]  A. Steinberg,et al.  The pathogenesis of autoimmunity in New Zealand mice, I. Induction of antinucleic acid antibodies by polyinosinic-polycytidylic acid. , 1969, Proceedings of the National Academy of Sciences of the United States of America.

[128]  M. Madaio,et al.  Interferon-α accelerates murine systemic lupus erythematosus in a T cell-dependent manner. , 2011, Arthritis and rheumatism.

[129]  T. Niewold,et al.  Age-and Gender-Specific Modulation of Serum Osteopontin and Interferon Alpha by Osteopontin Genotype in Systemic Lupus Erythematosus , 2009 .

[130]  F. Dammacco,et al.  Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. , 2008, Arthritis and rheumatism.

[131]  J. Harley,et al.  High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. , 2007, Genes and immunity.

[132]  A. Blangy,et al.  Interferon-alpha and -beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[133]  M. Peterson,et al.  Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. , 2004, Arthritis and rheumatism.

[134]  V. Pascual,et al.  Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. , 2001, Science.

[135]  B. Williams,et al.  Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. , 1998, Proceedings of the National Academy of Sciences of the United States of America.